CBD Science Group To Raise $2.7M Via EIS Approved Series A Funding Round

CBD Science Group PLC is poised to raise funds via an EIS Approved Series A funding round on the Crowd for Angels platform.

The Series A Funding is a raise of £2 million ($2.75 million) at £0.50 per share on a £12.8 million pre-funding market valuation.

The London-based company develops cannabis-based treatments for cancer pain, recently received an endorsement from the National Cancer Research Institute of the UK.

CBD Science is pending regulatory approval of cannabis-based prescription drugs through a Real World Evidence, peer-reviewed clinical trial, which the National Cancer Research Institute has endorsed.

The development will help patients around the world to treat and manage cancer pain.

"Investments through this crowdfund will contribute to further R&D, ongoing clinical trial facilitation, working capital, and production/supply chain," Dr. Michael Raymont, CBD Science's CEO said Monday. "The company has consolidated partnerships with a number of leading oncology research centers across the UK and intends to initiate patient enrollment in Q1 of 2022."

Photo: Courtesy of Tara Winstead from Pexels

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsEducationFinancingMarketscancer painCBD Science GroupMichael Raymont
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!
CCC-Oct-24-Banner-1

Click on the image for more info.

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry?

Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. 

Get your tickets now before prices surge by following this link.